SignalFDA/Bio

Bristol Myers Reverses Lower Despite Double Phase 3 Win, As A Key Rival Crashes

Bristol Myers' double Phase 3 win offset by key rival crash, reversing gains.

Context

Bristol Myers Squibb reported two Phase 3 wins on Monday in lung disease and cancer. Despite the results, the stock fell.

What changed

Bristol Myers' double Phase 3 win offset by key rival crash, reversing gains.

Why it matters

Bristol Myers' double Phase 3 win offset by key rival crash, reversing gains. — impact context not separately stored; see What changed.

Sources